RisedronatE and ALendronate intervention over three years (REALITY): Minimal differences in fracture risk reduction

Osteoporosis International

Volumn 20, Issue 6, 2009, Pages 973-978

  Curtis, J R ^a,b   Westfall, A O ^a   Cheng, H ^a   Saag, K G ^a,b   Delzell, E ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Alendronate; Bisphosphonate; Fracture; Osteoporosis; Risedronate

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; DRUG EFFICACY; FEMALE; FRACTURE; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK REDUCTION; VERTEBRA FRACTURE;

AGED; ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; ETIDRONIC ACID; FEMALE; HIP FRACTURES; HUMANS; INCIDENCE; MEDICATION ADHERENCE; OSTEOPOROSIS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK REDUCTION BEHAVIOR; SPINAL FRACTURES; TREATMENT OUTCOME;

EID: 67349285806     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-008-0772-2     Document Type: Article

References (16)

1. DM Black SR Cummings DB Karpf 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures Lancet 348 1535 1541
2. SR Cummings DM Black DE Thompson WB Applegate E Barrett-Connor TA Musliner L Palermo R Prineas SM Rubin JC Scott T Vogt R Wallace AJ Yates AZ LaCroix 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures J Am Med Assoc 280 2077 2082
3. MR [tmp] McClung P Geusens PD Miller 2001 Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group N Engl J Med 344 5 333 340
4. ST Harris NB Watts HK Genant 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial JAMA 282 1344 1352
5. J Reginster HW Minne OH Sorensen 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group Osteoporos Int 11 1 83 91
6. S Bonnick KG Saag DP Kiel 2006 Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years J Clin Endocrinol Metab 91 7 2631 2637
7. JE Dunford K Thompson FP Coxon 2001 Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates J Pharmacol Exp Ther 296 2 235 242
8. GH Nancollas R Tang RJ Phipps 2006 Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite Bone 38 5 617 627
9. JR Green K Muller KA Jaeggi 1994 Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound J Bone Miner Res 9 5 745 751
10. SL Silverman NB Watts PD Delmas JL Lange R Lindsay 2007 Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study Osteoporos Int 18 1 25 34
11. K Saag R Lindsay A Kriegman E Beamer W Zhou 2007 A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density Bone 40 5 1238 1243
12. M [tmp] McClung R Recker P Miller 2007 Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate Bone 41 1 122 128
13. Curtis JR, Mudano AS, Solomon DH, Xi J, Melton ME, Saag KG (2008) Identification and validation of vertebral compression fractures using administrative claims data. Med Care (in press)
14. JR Curtis AO Westfall J Allison A Freeman SH Kovac KG Saag 2006 Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users Pharmacoepidemiol Drug Saf 15 10 710 718
15. JA Cramer MM Amonkar A Hebborn R Altman 2005 Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis Curr Med Res Opin 21 9 1453 1460
16. RA Deyo DC Cherkin MA Ciol 1992 Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases J Clin Epidemiol 45 6 613 619